Olaparib (5) (Lynparza®) – Ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma, FIGO stages III and IV, HRD-positive, maintenance therapy, combination with bevacizumab

Characteristics

Start date 01.12.2020
Resolution 03.06.2021
Limitation date 01.10.2022, limitation changed to 01.12.2022
INN Olaparib
Brand name Lynparza®
Pharm. company AstraZeneca GmbH
G-BA procedure ID 2020-12-01-D-616
ATC code L01XK01
ICD-10 codes C48.0Malignant neoplasm of retroperitoneum, C48.1Malignant neoplasm of cul-de-sac, C48.2Malignant neoplasm of peritoneum, unspecified, C48.8Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum, C56Malignant neoplasm of ovary, C57.0Malignant neoplasm of oviduct, C57.1Malignant neoplasm of broad ligament, C57.3Malignant neoplasm of uterine ligament NOS, C57.4Malignant neoplasm of uterine adnexa, unspecified
DDD 0.8 g O
Therapeutic area Oncological diseases
Reason for procedure New Indication

Indication (German)

Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

Subpopulation Indication Comparator
Adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma who have a response (complete or partial) after completion of first-line platinum-based chemotherapy in combination with bevacizumab; disease associated with homologous recombination deficiency (defined by either a BRCA1/2 mutation and/or genomic instability); maintenance therapy. The continuation of treatment with bevacizumab started with platinum-based first-line chemotherapy

9. Associated procedures



<< List of all resolutions